Greenbrook TMS Inc
TSX:GTMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (29.4), the stock would be worth CA$-7.56 (880% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.8 | CA$0.97 |
0%
|
| Industry Average | 29.4 | CA$-7.56 |
-880%
|
| Country Average | 14.5 | CA$-3.72 |
-484%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Greenbrook TMS Inc
TSX:GTMS
|
28.6m CAD | -3.8 | -0.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97.1B USD | 14 | 54.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 9.9 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.4B USD | 0 | 12.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.9B EUR | 14.2 | 18.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23B EUR | 16.8 | 23.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.4B USD | 16.5 | 22.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD | 17.7 | 25.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 9.9 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.7B USD | -27.9 | -28.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 9.8 | 14 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.6 |
| Median | 14.5 |
| 70th Percentile | 20.6 |
| Max | 3 794.4 |
Other Multiples
Greenbrook TMS Inc
Glance View
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. The company is headquartered in Toronto, Ontario and currently employs 430 full-time employees. The company went IPO on 2018-10-03. The TMS therapy is a non-invasive therapy for the treatment of depressive disorder (MDD) and other mental health disorders. The TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. The firm's patient-focused, customer service model provides TMS therapy accessible to all patients through three business processes: Patient Inquiry; Patient Conversion; and Treatment Delivery. A course of TMS consists of 36 treatments and a course of treatment consist of an initial cortical mapping and motor threshold determination and treatment, daily treatment sessions and a subsequent motor threshold re-determination and treatment. The company operates through approximately 130 Company-operated treatment centers. The company operates across the States of North Carolina, South Carolina, Maryland, Delaware, Missouri, Illinois, and Ohio.
